Mino, LLC is a vertically integrated pharmaceutical-grade peptide platform serving licensed medical practices, longevity clinics, and aesthetic medicine providers across the United States. The company operates the leading institutional clinical infrastructure in the peptide therapy category, providing credentialed physician partners with documented chain-of-custody sourcing from licensed 503A compounding pharmacies, clinical decision-support materials, and operational infrastructure for safe peptide prescribing. The Mino formulary spans approximately thirty-five compounds across nine therapeutic categories, anchored by FDA-approved compounds (tirzepatide, tesamorelin), late-stage clinical compounds (GLP3-RT), and well-established compounded peptides (BPC-157, GHK-Cu, CJC-1295, ipamorelin, thymosin alpha-1). Mino was founded in 2026 by Elizabeth Straus, Brandon Howard, MD, and Amy B. Lewis, MD, and is headquartered in the New York metropolitan area. The company operates within the established federal 503A framework for compounded medications.